Brookings Report Examines Revenue Streams, Profitability Of HIV Treatments

Brookings Institution’s “TechTank”: How profitable are HIV drugs?
Jake Schneider, research assistant, and Darrell West, vice president and director of governance studies and founding director of the Center for Technology Innovation, both at the Brookings Institution, discuss findings from their newly released report examining the estimated potential returns to private investors in antiretroviral therapies and the profitability of HIV drugs in various countries and regions. The authors offer several recommendations for how to overcome barriers to investment in emerging markets (4/16).